Clinical Trial Update: Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) [Phase 2]

View source ↗

Summary

This Clinical Trial Update reports a Phase 2 study comparing daratumumab to rituximab for pediatric primary immune thrombocytopenia, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Daratumumab (daratumumab)
• Rituximab (rituximab)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Immune Thrombocytopenia, Treatment | Phase 2 | Status: RECRUITING